Department of Biomedical Engineering, Institute for NanoBioTechnology, and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Department of Biomedical Engineering, Institute for NanoBioTechnology, and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Departments of Ophthalmology, Oncology, Neurosurgery, Materials Science & Engineering, and Chemical & Biomolecular Engineering, and the Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Adv Drug Deliv Rev. 2021 Dec;179:113999. doi: 10.1016/j.addr.2021.113999. Epub 2021 Oct 27.
Glioblastoma (GBM) is an aggressive central nervous system cancer with a dismal prognosis. The standard of care involves surgical resection followed by radiotherapy and chemotherapy, but five-year survival is only 5.6% despite these measures. Novel therapeutic approaches, such as immunotherapies, targeted therapies, and gene therapies, have been explored to attempt to extend survival for patients. Nanoparticles have been receiving increasing attention as promising vehicles for non-viral nucleic acid delivery in the context of GBM, though delivery is often limited by low blood-brain barrier permeability, particle instability, and low trafficking to target brain structures and cells. In this review, nanoparticle design considerations and new advances to overcome nucleic acid delivery challenges to treat brain cancer are summarized and discussed.
胶质母细胞瘤（GBM）是一种侵袭性中枢神经系统癌症，预后不良。标准治疗包括手术切除，然后进行放疗和化疗，但尽管采取了这些措施，五年生存率仅为 5.6%。为了延长患者的生存时间，已经探索了新的治疗方法，如免疫疗法、靶向治疗和基因治疗。纳米颗粒作为非病毒核酸在 GBM 治疗中传递的有前途的载体，越来越受到关注，尽管传递通常受到血脑屏障通透性低、颗粒不稳定以及向靶脑结构和细胞转运低的限制。在这篇综述中，总结和讨论了纳米颗粒设计考虑因素和克服核酸传递挑战以治疗脑癌的新进展。
